The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
2022: Accelerated Therapeutics Program, 2022Translation of the Neuroprotective Immune Modulator LBT-3627 into First-In-Human Studies
Study Rationale: LBT-3627 is a disease-modifying therapeutic candidate that has been shown to reduce brain inflammation and immune imbalance in preclinical models of Parkinson's disease (PD). A recent...
-
Fall 2021 RFA: Promoting Diversity, Equity and Inclusion in Parkinson’s Disease Research, 2022Disparities in Neurocognitive Impairment Among Hispanics and Latinos in the United States with Parkinson’s Disease: The Role of Cardiovascular Risk
Study Rationale: In the United States, Latinos with Parkinson’s disease (PD) are more likely to have problems with memory, planning and other thinking skills than individuals of other ethnic/racial...
-
Diversity, Equity and Inclusivity in Parkinson's research, 2022Identifying Barriers and Motivators Associated with Access to Care and Participation in Genetic Research Studies for Parkinson's Disease among Asian Americans
Study Rationale: Clinicians have observed that Asian Americans are older and have had symptoms for a longer period of time than Whites when they are diagnosed with Parkinson’s disease (PD). In...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2022Assessment of Alpha-synuclein Aggregation Inhibitor ASN121151 as a Potential New Treatment for Parkinson’s Disease
Study Rationale: Genetic defects in the gene encoding alpha-synuclein cause the protein to aggregate in the brains of people with a familial form of Parkinson’s disease (PD). We have developed a novel...
-
Fall 2020 RFA: Therapeutic Pipeline Program-Pre-Clinical, 2022Targeting Colony-stimulating Factor 1 Receptor (CSF1R) to Modify Disease Progression in Preclinical Experimental Models of Parkinson’s Disease
Study Rationale: Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by pronounced neuroimmune dysfunction. Although the disease is very common, no therapy is available...
-
2022: Accelerated Therapeutics Program, 2022Using Small Molecules that Modulate Mitochondrial Function for the Treatment of Parkinson's Disease
Study Rationale: Dysfunction in energy-producing structures called mitochondria is a crucial driver of the initiation and progression of Parkinson’s disease (PD). Mitochondria in the cells of people...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.